Kamada (NASDAQ:KMDA) & Neurogene (NASDAQ:NGNE) Head-To-Head Analysis

Kamada (NASDAQ:KMDA) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and price targets for Kamada and Neurogene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0	0	2	0	3.00
Neurogene	0	0	8	1	3.11

Kamada presently has a consensus price target of $14.50, indicating a potential upside of 176.72%. Neurogene has a consensus price target of $51.00, indicating a potential upside of 27.69%. Given Kamada’s higher possible upside, analysts clearly believe Kamada is more favorable than Neurogene.

Profitability

This table compares Kamada and Neurogene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kamada	9.75%	6.15%	4.35%
Neurogene	N/A	-32.44%	-27.70%

Valuation and Earnings

This table compares Kamada and Neurogene”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$154.57 million	1.95	$8.28 million	$0.23	22.78
Neurogene	$925,000.00	560.46	-$36.32 million	N/A	N/A

Kamada has higher revenue and earnings than Neurogene.

Institutional and Insider Ownership

20.4% of Kamada shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 9.9% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Kamada has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Summary

Kamada beats Neurogene on 7 of the 13 factors compared between the two stocks.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.